IMAXIO is an integrated biotech company focused on vaccines and genomics, and based on the combination of R&D and commercial activities:
IMX313 TECHNOLOGY PLATFORM: a technology platform using recombinant carrier proteins to develop immunostimulant vaccines against several infectious diseases (1st human clinical trial planned for 2013).
SPIROLEPT®: a vaccine against human leptospirosis marketed in France.
GENOMICS PLATFORM: a R&D and services platform in genomics for the development of companion diagnostic tests in immunology and oncology.
IMAXIO was formed in 2006 by the merger of Diagnogene and Avidis (a spin-off developed in 2000 by the Medical Research Council and the University of Cambridge in the UK). It owns solid intellectual property and collaborates with numerous academic and industrial partners, including the Jenner Institute at Oxford University (UK). IMAXIO is also a member of 2 research structures:
Lyonbiopôle (infectiology) CLARA (oncology)
In 2011, IMAXIO has a turnover of € 2.4 Million. It wants to strengthen it over the next 3 years with the acquisition of 2 or 3 pharmaceutical products already marketed in France or in Europe. Finally, in order to pursue the development of its proprietary technology IMX313, IMAXIO is seeking partners, and is looking in particular for companies which own proprietary antigens.